Company profile
REPLIGEN CORP
NASDAQ:RGENBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| URIDINE TRIACETATE | phase1 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00812058 | phase2 | completed | 2008-11-01 | 2010-12-01 | Repligen Corporation | A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression |
| NCT00322764 | phase2 | completed | 2006-03-01 | — | Repligen Corporation | Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression |
| NCT00060515 | phase1 | terminated | — | — | Repligen Corporation | RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease |
| NCT00660335 | phase3 | completed | 2008-03-01 | 2009-10-01 | Repligen Corporation | Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas |
| NCT00036244 | phase3 | completed | 2002-04-01 | — | Repligen Corporation | Synthetic Human Secretin in Children With Autism |
FDA applications (0)
No records yet.